Siemens Introduces a New Generation in Preclinical Imaging at AMI
Inveon Enhances Research and Drug Discovery.
Orlando, Fla., Mar 24, 2006, Siemens Medical Solutions today introduced InveonTM, a new generation in preclinical imaging. Available as a modular or integrated system, this unique imaging platform enables researchers to leverage any combination of Siemens’ preclinical hybrid imaging systems and leading edge applications for improved research opportunities. Inveon and other innovations from Siemens Molecular Imaging Division can be seen at the Academy of Molecular Imaging (AMI) meeting from March 25 - 29, in Orlando, Fla. (booth # 107).
“Siemens preclinical solutions are driving medical research from the laboratory to the clinic,” said Michael Reitermann, president, Molecular Imaging Division, Siemens Medical Solutions. “Inveon offers limitless solutions and the highest performance and versatility available to address research needs from academic and translational research, to drug discovery and development.”
Molecular medicine combines advanced imaging with molecular biomarkers to enable the identification of disease pathways and evaluate the actions of novel therapies. As more disease-specific biomarkers are developed, researchers may be able to increase the speed at which drugs come to market. Inveon can help facilitate basic research as well as the drug development process, empowering researchers to identify specific biological processes, monitor the efficacy of compounds, and measure the effects of disease progression over time.
Inveon represents a new preclinical, multimodality imaging solution that offers a versatile and upgradeable platform as well as a comprehensive suite of preclinical analysis applications. The system enables unified control of Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and CT data acquisition, and offers the industry’s highest PET resolution and sensitivity. Inveon features advanced multi-pinhole SPECT collimators for improved sensitivity and spatial resolution; groundbreaking new PET and SPECT acquisition and processing technology; and a unique PET transmission method for faster and more accurate attenuation correction.
Inveon offers researchers the convenience of a multimodality platform with the potential throughput of two independent scanners. A dedicated PET module can be used as a standalone, high-performance small animal imaging system, or docked onto the Inveon gantry, housing CT and/or SPECT modules. When in the docked configuration, the system can operate independently or as a single unit under the control of one workstation. Inveon’s integrated and modular configurations are customizable to specific needs, optimizing throughput and making PET/CT, CT/SPECT, or PET/CT/SPECT configurations possible.
Enhanced Applications Optimize Workflow
In addition to enhanced imaging capabilities, Siemens has expanded its preclinical applications, which includes the most comprehensive suite of reconstruction algorithms offered in the industry. Inveon offers optimized data acquisition and state of the art image fusion technology, high end integrated visualization and analysis capabilities, and comprehensive preclinical data analysis and post process applications.
Also at AMI
In addition to the new Inveon system, Siemens will introduce a new 40-slice configuration to its Biograph® family of PET/CT systems. The Biograph family -- which consists of two-, six-, 16-, 40- and 64-slice configurations -- is the most comprehensive PET/CT product offering on the market today, providing clinicians with unmatched imaging clarity and diagnostic confidence for applications such as oncology management and cardiac assessment.
Other highlights include, Siemens Symbia® family of SPECT technology, which incorporates flexible, scalable system architecture to deliver a variety of models, ranging from systems that offer attenuation correction to premium, multislice CT capabilities; clinical applications such as syngo® TrueD, syngo Scenium, and syngo CardioFusion, designed for optimized workflow; PETNET® Pharmaceuticals, the world’s leading producer and distributor of PET biomarkers; the ECLIPSETM family of cyclotrons and Explora radiochemistry synthesis products for developing and producing tracers that help characterize, quantify, and visualize the biology of disease.
About Siemens Medical Solutions
Siemens Medical Solutions of Siemens AG (NYSE:SI) with headquarters in Malvern, Pennsylvania, and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Employing approximately 33,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.6 billion EUR and group profit of 976 million EUR for fiscal 2005. More information can be obtained by visiting www.usa.siemens.com/medical-pressroom.
PHOTOGRAPHY AVAILABLE UPON REQUEST
- Contact Information
- Amanda Naiman
- Public Relations Manager
- Siemens AG
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.